EXOZYMES INC.
EXOZYMES INC.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||
Cash And Cash Equivalents At Carrying Value | 6 | 1 | 3 | 5 | 7 | 9 | 10 | 0 | |||||
Grants Receivable Current | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | |||||
Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
Assets Current | 6 | 2 | 4 | 6 | 8 | 9 | 11 | 1 | |||||
Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Finance Lease Right Of Use Asset | - | 0 | 0 | 0 | 0 | - | - | - | |||||
Income Taxes Receivable Noncurrent | - | - | - | 0 | - | - | - | - | |||||
Deferred Income Tax Assets Net | 0 | 0 | 0 | - | - | - | - | - | |||||
Assets | 8 | 4 | 6 | 8 | 10 | 12 | 13 | 4 | |||||
Liabilities And Stockhold… | |||||||||||||
Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Other Liabilities Current | - | 0 | 0 | 0 | - | 0 | 0 | - | |||||
Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Finance Lease Liability Current | - | 0 | 0 | 0 | 0 | - | - | - | |||||
Liabilities Current | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 6 | |||||
Deferred Income Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Finance Lease Liability Noncurrent | - | 0 | 0 | 0 | 0 | - | - | - | |||||
Liabilities | 4 | 2 | 3 | 2 | 2 | 3 | 3 | 7 | |||||
Stockholders Equity | |||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 30 | 25 | 25 | 24 | 23 | 23 | 22 | 7 | |||||
Retained Earnings Accumulated Deficit | -26 | -23 | -21 | -18 | -16 | -14 | -12 | -10 | |||||
Stockholders Equity | 4 | 2 | 3 | 5 | 7 | 9 | 10 | -4 | |||||
Liabilities And Stockholders Equity | 8 | 4 | 6 | 8 | 10 | 12 | 13 | 4 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Issued | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 6 | |||||
Shares Outstanding | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 6 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.79% | -15.37% | -54.09% | - | - | - | - | - | - | - | - | - |
| 2025 | 7.15% | -20.97% | -19.66% | 19.21% | 32.56% | 43.53% | -10.21% | -32.99% | -36.59% | 41.23% | 35.89% | 7.26% |
| 2024 | - | - | - | - | - | - | - | - | - | 2.68% | 42.58% | -12.44% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
EXOZYMES INC. (EXOZ) — SEC Financial Statements & Analysis
EXOZYMES INC. (EXOZ) is a biological products, (no diagnostic substances) company, incorporated in NV. EXOZYMES INC. trades on Nasdaq as: EXOZ. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), EXOZYMES INC. reported a Debt-to-Equity ratio of 1.18x, a Price-to-Book (P/B) ratio of 19.98x (TTM), at a market cap of $73.01M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 1.18x
- P/B TTM
- 19.98x
- Market Cap
- $73.01M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is EXOZYMES INC. in?
EXOZYMES INC. (EXOZ) operates in the Biological Products, (No Diagnostic Substances) industry.
What is EXOZ's market cap?
EXOZYMES INC. (EXOZ) has a market capitalization of $73.01M as of 2026-06-30.
What exchange does EXOZ trade on?
EXOZYMES INC. (EXOZ) trades on the Nasdaq.
Where is EXOZYMES INC. incorporated?
EXOZYMES INC. is incorporated in NV.